Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The European Medicine Agency's outgoing Executive Director Thomas Lönngren discusses his 10 years on the job, the importance of regulatory science and the challenges that lie ahead for his successor.
The Senior Vice President of Medicines Discovery and Development at GlaxoSmithKline discusses the rationale for the recent evolution of the company's research and development strategy.
The Head of Global Scientific Strategy at Merck Research laboratories discusses research and development priorities at Merck following their merger with Schering–Plough.
The new President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation discusses how his experience of leading Wyeth Vaccines will help the organization to reach its goal.
The Chairman of Biocon Limited — India's largest biotechnology company — discusses how the country could move from being a service provider to being a source of novel therapies in the future.
The Head of the Clinical Trials Unit at the Paul Ehrlich Institute in Germany discusses the progress of a 'one stop shop' to assess applications for multinational clinical trials in Europe.
The Executive Director of US think tankFasterCuresdiscusses how the organization acts as a catalyst to accelerate the development of innovative therapies.
A pioneer of evidence-based medicine discusses how mathematical models can be used to understand the likely cost and health-care outcomes of therapies.